marketcaparena
Search

    MIRM

    Mirum Pharmaceuticals, Inc.

    Company overview

    Market capitalization
    $5.71B
    Employees
    418
    Latest publication
    2026-09-29
    About Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20252025-09-30 · USDQ3 20212021-09-30 · USDQ2 20212021-06-30 · USDQ1 20212021-03-31 · USDQ4 20202020-12-31 · USDQ3 20202020-09-30 · USDQ2 20202020-06-30 · USD
    Total Revenue176,243,000USD133,010,000USD5,000,000USD11,000,000USD0USD0USD0USD0USD
    Research Development90,528,000USD42,960,000USD30,471,000USD35,048,000USD38,134,000USD29,726,000USD15,984,000USD18,555,000USD
    Selling General Administrative81,469,000USD61,910,000USD17,353,000USD13,353,000USD9,479,000USD7,225,000USD5,732,000USD5,042,000USD
    Total Operating Expenses218,780,000USD104,870,000USD47,824,000USD48,401,000USD47,613,000USD36,951,000USD21,716,000USD23,597,000USD
    Operating Income-42,537,000USD2,603,000USD-42,824,000USD-37,401,000USD-47,613,000USD-36,951,000USD-21,716,000USD-23,597,000USD
    Total Other Income Expense Net-23,001,000USD40,000USD-4,275,000USD-6,482,000USD-2,914,000USD-250,000USD207,000USD349,000USD
    Interest Income3,851,000USD3,251,000USD72,000USD80,000USD149,000USD168,000USD237,000USD405,000USD
    Interest Expense2,618,000USD3,606,000USD5,667,000USD4,776,000USD3,381,000USD335,000USD237,000USD405,000USD
    Income Before Tax-65,538,000USD2,643,000USD-47,099,000USD-43,883,000USD-50,527,000USD-37,201,000USD-21,509,000USD-23,248,000USD
    Income Tax Expense1,689,000USD-262,000USD9,000USD11,000USD5,000USD2,000USD-3,000USD3,000USD
    Net Income-67,227,000USD2,905,000USD-47,108,000USD-43,894,000USD-50,532,000USD-37,203,000USD-21,506,000USD-23,251,000USD
    Net Income Applicable To Common Shares-67,227,000USD—-47,108,000USD-43,894,000USD-50,532,000USD-37,203,000USD-21,506,000USD-23,251,000USD
    Cost Of Revenue30,348,000USD25,537,000USD——185,000USD———
    Gross Profit—107,473,000USD5,000,000USD11,000,000USD-185,000USD———
    Net Interest Income—-355,000USD-5,595,000USD-4,696,000USD-3,232,000USD-167,000USD237,000USD405,000USD
    Tax Provision—-262,000USD9,000USD11,000USD5,000USD2,000USD-3,000USD3,000USD
    Net Income From Continuing Ops—2,905,000USD-47,108,000USD-43,894,000USD-50,532,000USD-37,203,000USD-21,506,000USD-23,251,000USD
    Ebit—2,998,000USD-41,432,000USD-39,107,000USD-47,146,000USD-35,584,000USD-21,509,000USD-23,248,000USD
    Ebitda—9,060,000USD-41,254,000USD-38,932,000USD-46,961,000USD-35,419,000USD-21,354,000USD-23,101,000USD
    Depreciation And Amortization—6,062,000USD178,000USD175,000USD185,000USD165,000USD155,000USD147,000USD
    Reconciled Depreciation—6,062,000USD178,000USD175,000USD185,000USD165,000USD155,000USD147,000USD
    Non Operating Income Net Other——37,000USD-434,000USD133,000USD———
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Total Revenue19,138,000USD11,000,000USD0USD
    Cost Of Revenue1,903,000USD623,000USD324,000USD
    Gross Profit17,235,000USD-623,000USD-324,000USD
    Research Development131,428,000USD81,605,000USD42,991,000USD
    Selling General Administrative50,020,000USD22,691,000USD11,752,000USD
    Selling And Marketing Expenses9,200,000USD——
    Total Operating Expenses190,648,000USD103,673,000USD54,743,000USD
    Operating Income-173,413,000USD-104,296,000USD-54,743,000USD
    Interest Income366,000USD1,559,000USD2,232,000USD
    Interest Expense17,590,000USD335,000USD2,535,000USD
    Net Interest Income-17,224,000USD1,224,000USD2,232,000USD
    Income Before Tax-83,951,000USD-103,264,000USD-52,532,000USD
    Income Tax Expense37,000USD6,000USD21,000USD
    Tax Provision37,000USD6,000USD21,000USD
    Net Income-83,988,000USD-103,270,000USD-52,553,000USD
    Net Income From Continuing Ops-83,988,000USD-103,270,000USD-52,553,000USD
    Ebit-66,361,000USD-102,929,000USD-54,743,000USD
    Ebitda-65,386,000USD-102,306,000USD-54,419,000USD
    Depreciation And Amortization975,000USD623,000USD324,000USD
    Reconciled Depreciation975,000USD623,000USD324,000USD
    Total Other Income Expense Net89,462,000USD1,032,000USD2,211,000USD
    Non Operating Income Net Other-216,000USD1,367,000USD—
    Net Income Applicable To Common Shares-83,988,000USD-103,270,000USD-52,553,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets1,044,981,000USD890,916,000USD842,813,000USD785,115,000USD725,825,000USD690,245,000USD670,754,000USD667,893,000USD
    Cash And Equivalents330,728,000USD———————
    Cash And Short Term Investments438,291,000USD386,259,000USD383,327,000USD375,548,000USD304,552,000USD277,674,000USD280,315,000USD284,445,000USD
    Short Term Investments107,563,000USD61,352,000USD86,644,000USD93,527,000USD76,430,000USD65,852,000USD57,812,000USD61,476,000USD
    Long Term Investments123,030,000USD34,353,000USD8,105,000USD2,470,000USD17,112,000USD20,912,000USD12,526,000USD9,321,000USD
    Total Current Assets636,310,000USD569,436,000USD549,684,000USD530,575,000USD453,398,000USD410,818,000USD392,788,000USD386,626,000USD
    Other Current Assets26,890,000USD24,546,000USD18,140,000USD23,874,000USD19,069,000USD14,874,000USD11,784,000USD12,057,000USD
    Other Non Current Assets22,244,000USD———————
    Total Liabilities1,055,403,000USD———————
    Total Current Liabilities222,788,000USD272,824,000USD205,799,000USD160,359,000USD144,796,000USD127,577,000USD126,551,000USD115,751,000USD
    Other Non Current Liabilities10,917,000USD———————
    Total Stockholder Equity-10,422,000USD242,494,000USD314,690,000USD292,046,000USD255,158,000USD233,256,000USD225,640,000USD232,024,000USD
    Total Equity Including Noncontrolling Interest-10,422,000USD———————
    Net Receivables145,360,000USD133,113,000USD123,330,000USD107,132,000USD106,836,000USD95,852,000USD78,286,000USD68,530,000USD
    Inventory25,769,000USD25,518,000USD24,887,000USD24,021,000USD22,941,000USD22,418,000USD22,403,000USD21,594,000USD
    Property Plant Equipment Net14,275,000USD15,059,000USD10,603,000USD9,777,000USD10,123,000USD8,771,000USD9,814,000USD10,347,000USD
    Intangible Assets247,388,000USD254,154,000USD260,921,000USD231,895,000USD237,870,000USD243,845,000USD249,819,000USD255,794,000USD
    Accounts Payable23,427,000USD59,399,000USD9,614,000USD12,167,000USD17,657,000USD11,639,000USD14,618,000USD9,545,000USD
    Short Term Debt2,405,000USD2,353,000USD2,139,000USD2,035,000USD2,081,000USD1,644,000USD1,709,000USD1,506,000USD
    Common Stock6,000USD6,000USD5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD
    Retained Earnings-1,524,926,000USD-1,457,699,000USD-667,544,000USD-661,814,000USD-664,719,000USD-658,858,000USD-644,181,000USD-620,391,000USD
    Accumulated Other Comprehensive Income-674,000USD-28,000USD351,000USD37,000USD352,000USD-258,000USD-373,000USD920,000USD
    Total Liab—648,422,000USD528,123,000USD493,069,000USD470,667,000USD456,989,000USD445,114,000USD435,869,000USD
    Other Current Liab—211,072,000USD194,046,000USD146,157,000USD125,058,000USD114,294,000USD110,224,000USD104,700,000USD
    Capital Stock—6,000USD5,000USD5,000USD5,000USD5,000USD5,000USD5,000USD
    Cash—324,907,000USD296,683,000USD282,021,000USD228,122,000USD211,822,000USD222,503,000USD222,969,000USD
    Net Debt—-1,128,000USD22,769,000USD36,743,000USD90,776,000USD105,334,000USD95,260,000USD94,683,000USD
    Short Long Term Debt Total—323,779,000USD319,452,000USD318,764,000USD318,898,000USD317,156,000USD317,763,000USD317,652,000USD
    Long Term Debt—310,251,000USD309,797,000USD309,368,000USD308,933,000USD308,509,000USD308,082,000USD307,666,000USD
    Property Plant Equipment Gross—15,059,000USD10,603,000USD9,777,000USD10,123,000USD8,771,000USD9,814,000USD10,347,000USD
    Common Stock Shares Outstanding—58,851,021shares50,198,304shares56,993,841shares49,726,823shares48,889,058shares48,338,096shares47,782,619shares
    Non Current Assets Total—321,480,000USD293,129,000USD254,540,000USD272,427,000USD279,427,000USD277,966,000USD281,267,000USD
    Non Current Liabilities Total—375,598,000USD322,324,000USD332,710,000USD325,871,000USD329,412,000USD318,563,000USD320,118,000USD
    Non Current Liabilities Other—54,172,000USD5,011,000USD—9,054,000USD13,900,000USD2,509,000USD3,972,000USD
    Non Currrent Assets Other—17,914,000USD13,500,000USD10,398,000USD7,322,000USD5,899,000USD5,807,000USD5,805,000USD
    Net Working Capital—296,612,000USD343,885,000USD370,216,000USD308,602,000USD283,241,000USD266,237,000USD270,875,000USD
    Unclassified Non Current Liabilities—11,175,000USD7,516,000USD23,342,000USD7,884,000USD7,003,000USD7,972,000USD8,480,000USD
    Unclassified Equity—1,700,209,000USD981,873,000USD953,813,000USD919,515,000USD892,362,000USD870,184,000USD851,485,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets842,813,000USD670,754,000USD646,621,000USD352,906,000USD294,651,000USD240,864,000USD146,712,000USD51,975,000USD
    Intangible Assets260,921,000USD249,819,000USD252,925,000USD58,954,000USD18,740,000USD——0USD
    Other Current Assets18,140,000USD11,784,000USD10,935,000USD8,947,000USD4,171,000USD4,530,000USD2,703,000USD24,000USD
    Total Liab528,123,000USD445,114,000USD397,951,000USD210,869,000USD174,439,000USD68,769,000USD16,363,000USD62,298,000USD
    Total Stockholder Equity314,690,000USD225,640,000USD248,670,000USD142,037,000USD120,212,000USD172,095,000USD130,349,000USD-10,323,000USD
    Other Current Liab194,046,000USD110,224,000USD78,544,000USD55,108,000USD32,719,000USD14,675,000USD9,328,000USD2,180,000USD
    Common Stock5,000USD5,000USD5,000USD4,000USD3,000USD3,000USD2,000USD6,991,000USD
    Capital Stock5,000USD5,000USD5,000USD4,000USD3,000USD3,000USD2,000USD6,991,000USD
    Retained Earnings-667,544,000USD-644,181,000USD-556,239,000USD-392,824,000USD-257,159,000USD-173,171,000USD-69,901,000USD-17,348,000USD
    Cash296,683,000USD222,503,000USD286,326,000USD28,003,000USD31,340,000USD142,086,000USD11,970,000USD51,963,000USD
    Cash And Short Term Investments383,327,000USD280,315,000USD286,326,000USD151,719,000USD156,541,000USD231,820,000USD116,660,000USD51,963,000USD
    Total Current Assets549,684,000USD392,788,000USD387,541,000USD190,225,000USD166,592,000USD236,350,000USD119,363,000USD51,975,000USD
    Total Current Liabilities205,799,000USD126,551,000USD87,064,000USD64,729,000USD42,596,000USD18,462,000USD13,076,000USD2,449,000USD
    Net Debt22,769,000USD95,260,000USD21,816,000USD-25,815,000USD-28,726,000USD-138,823,000USD-8,322,000USD-51,963,000USD
    Short Term Debt2,139,000USD1,709,000USD1,104,000USD931,000USD711,000USD636,000USD397,000USD0USD
    Short Long Term Debt Total319,452,000USD317,763,000USD308,142,000USD2,188,000USD2,614,000USD3,263,000USD3,648,000USD—
    Long Term Debt309,797,000USD308,082,000USD306,421,000USD————0USD
    Long Term Investments8,105,000USD12,526,000USD0USD0USD4,983,000USD0USD23,292,000USD0USD
    Short Term Investments86,644,000USD57,812,000USD0USD123,716,000USD125,201,000USD89,734,000USD104,690,000USD0USD
    Net Receivables123,330,000USD78,286,000USD67,968,000USD23,994,000USD4,367,000USD0USD——
    Inventory24,887,000USD22,403,000USD22,312,000USD5,565,000USD1,513,000USD0USD—0USD
    Accounts Payable9,614,000USD14,618,000USD7,416,000USD8,690,000USD9,166,000USD3,151,000USD3,351,000USD269,000USD
    Property Plant Equipment Net10,603,000USD9,814,000USD1,990,000USD2,345,000USD2,550,000USD3,242,000USD3,733,000USD0USD
    Property Plant Equipment Gross10,603,000USD9,814,000USD1,990,000USD2,345,000USD2,550,000USD3,242,000USD3,733,000USD0USD
    Accumulated Other Comprehensive Income351,000USD-373,000USD1,644,000USD-217,000USD-35,000USD83,000USD129,000USD-66,839,000USD
    Common Stock Shares Outstanding50,198,304shares47,523,000shares40,885,124shares33,982,493shares30,321,722shares25,251,968shares22,989,987shares22,989,987shares
    Non Current Assets Total293,129,000USD277,966,000USD259,080,000USD162,681,000USD128,059,000USD4,514,000USD27,349,000USD0USD
    Non Current Liabilities Total322,324,000USD318,563,000USD310,887,000USD146,140,000USD131,843,000USD50,307,000USD3,287,000USD59,849,000USD
    Non Current Liabilities Other5,011,000USD2,509,000USD3,849,000USD146,140,000USD131,843,000USD50,307,000USD36,000USD0USD
    Non Currrent Assets Other13,500,000USD5,807,000USD4,165,000USD101,382,000USD101,786,000USD1,272,000USD324,000USD0USD
    Net Working Capital343,885,000USD266,237,000USD300,477,000USD125,496,000USD123,996,000USD217,888,000USD106,287,000USD49,526,000USD
    Unclassified Non Current Liabilities7,516,000USD7,972,000USD—-144,883,000USD-130,140,000USD-47,680,000USD3,215,000USD52,859,000USD
    Unclassified Equity981,873,000USD870,184,000USD803,255,000USD535,070,000USD377,400,000USD345,177,000USD200,117,000USD59,882,000USD
    Other Assets——1USD101,382,000USD101,786,000USD3,221,000USD324,000USD0USD
    Current Deferred Revenue——-1,104,000USD—30,723,000USD13,411,000USD——
    Other Liab———144,883,000USD129,940,000USD47,680,000USD36,000USD6,990,000USD
    Net Tangible Assets———83,083,000USD101,472,000USD172,095,000USD130,349,000USD-17,313,000USD
    Unclassified Non Current Assets———-101,382,000USD-101,786,000USD-3,221,000USD——
    Deferred Long Term Liab————200,000USD——0USD
    Unclassified Current Liabilities————-30,723,000USD-13,411,000USD——
    Good Will———————0USD
    Short Long Term Debt———————0USD
    Accumulated Depreciation———————0USD
    Additional Paid In Capital———————0USD
    Treasury Stock———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation13,810,000USD
    Stock Based Compensation66,775,000USD
    Other Non Cash Items577,000USD
    Change To Account Receivables-26,630,000USD
    Change To Inventory-1,525,000USD
    Change In Working Capital-46,500,000USD
    Operating Cash Flow-273,015,000USD
    Capital Expenditures-687,000USD
    Net Investments-135,873,000USD
    Unclassified Investing Cash Flow-35,000,000USD
    Investing Cash Flow-171,560,000USD
    Common Stock Issuance23,499,000USD
    Unclassified Financing Cash Flow458,018,000USD
    Financing Cash Flow481,517,000USD
    Effect Of Forex Changes On Cash-2,645,000USD
    Change In Cash34,297,000USD
    End Cash Flow332,462,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-790,155,000USD-5,730,000USD2,905,000USD-5,861,000USD-14,677,000USD-23,790,000USD-14,235,000USD-24,638,000USD
    Depreciation6,874,000USD6,074,000USD6,062,000USD6,056,000USD6,052,000USD6,056,000USD6,055,000USD5,854,000USD
    Stock Based Compensation36,202,000USD19,026,000USD18,127,000USD18,468,000USD15,803,000USD13,251,000USD11,908,000USD11,835,000USD
    Other Non Cash Items416,097,000USD704,000USD442,000USD-67,000USD2,158,000USD1,097,000USD1,488,000USD1,583,000USD
    Change To Account Receivables-12,886,000USD-19,008,000USD-3,146,000USD-9,068,000USD-16,833,000USD-10,864,000USD-8,100,000USD-5,431,000USD
    Change To Inventory-1,920,000USD-2,282,000USD-1,159,000USD-2,335,000USD-2,672,000USD-214,000USD-903,000USD-1,085,000USD
    Change In Working Capital102,219,000USD-14,007,000USD12,145,000USD-6,556,000USD-11,297,000USD-1,682,000USD-1,232,000USD1,563,000USD
    Total Cash From Operating Activities-228,763,000USD6,067,000USD39,681,000USD12,040,000USD-1,961,000USD-5,068,000USD3,984,000USD-3,803,000USD
    Capital Expenditures-664,000USD-600,000USD-187,000USD-126,000USD-41,000USD-20,000USD-10,181,000USD-10,779,000USD
    Free Cash Flow-229,427,000USD5,467,000USD39,494,000USD11,914,000USD-2,002,000USD-5,088,000USD-6,197,000USD-14,582,000USD
    Investments-905,000USD1,606,000USD-2,227,000USD-6,599,000USD-16,134,000USD641,000USD-18,036,000USD-72,717,000USD
    Total Cashflows From Investing Activities-11,569,000USD1,006,000USD-2,227,000USD-6,599,000USD-16,134,000USD641,000USD-18,036,000USD-72,717,000USD
    Total Cash From Financing Activities270,079,000USD8,999,000USD16,096,000USD8,688,000USD6,359,000USD5,340,000USD3,863,000USD7,291,000USD
    Issuance Of Capital Stock259,948,000USD———0USD0USD0USD0USD
    Change In Cash28,224,000USD15,664,000USD53,899,000USD16,355,000USD-10,681,000USD-466,000USD-10,101,000USD-69,348,000USD
    Begin Period Cash Flow296,683,000USD282,501,000USD228,122,000USD212,247,000USD222,928,000USD223,394,000USD233,495,000USD302,843,000USD
    End Period Cash Flow324,907,000USD298,165,000USD282,021,000USD228,602,000USD212,247,000USD222,928,000USD223,394,000USD233,495,000USD
    Other Cashflows From Investing Activities-10,000,000USD—————-10,000,000USD-10,000,000USD
    Other Cashflows From Financing Activities270,079,000USD8,999,000USD16,096,000USD-6,359,000USD6,359,000USD5,340,000USD3,863,000USD7,291,000USD
    Unclassified Financing Cash Flow-259,948,000USD——15,047,000USD————
    Net Borrowings—————0USD0USD—
    Unclassified Investing Cash Flow——————20,181,000USD20,779,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-23,363,000USD-87,942,000USD-163,415,000USD-135,665,000USD-83,988,000USD-103,270,000USD-52,553,000USD-17,348,000USD
    Depreciation24,244,000USD23,629,000USD10,829,000USD3,681,000USD975,000USD623,000USD324,000USD324,000USD
    Stock Based Compensation71,424,000USD48,444,000USD35,023,000USD27,007,000USD23,087,000USD12,554,000USD6,070,000USD51,000USD
    Other Non Cash Items3,237,000USD3,603,000USD69,259,000USD12,471,000USD-90,410,000USD335,000USD-326,000USD12,089,000USD
    Change To Account Receivables-48,055,000USD-11,426,000USD-43,974,000USD-20,727,000USD-20,727,000USD-20,727,000USD-20,727,000USD0USD
    Change To Inventory-8,448,000USD-3,166,000USD-4,393,000USD-3,448,000USD-495,000USD-495,000USD-495,000USD-495,000USD
    Change In Working Capital-19,715,000USD22,591,000USD-22,640,000USD-21,050,000USD16,983,000USD611,000USD7,123,000USD2,437,000USD
    Total Cash From Operating Activities55,827,000USD10,325,000USD-70,944,000USD-120,136,000USD-132,758,000USD-89,075,000USD-39,362,000USD-373,000USD
    Capital Expenditures-954,000USD-993,000USD-20,109,000USD-278,000USD-19,024,000USD-225,000USD-281,000USD-7,500,000USD
    Free Cash Flow54,873,000USD9,332,000USD-91,053,000USD-120,414,000USD-151,782,000USD-89,300,000USD-39,643,000USD-7,873,000USD
    Investments-23,000,000USD-90,125,000USD-78,442,000USD7,978,000USD-42,429,000USD11,338,000USD-127,781,000USD-127,500,000USD
    Total Cashflows From Investing Activities-23,954,000USD-90,125,000USD-107,200,000USD7,700,000USD48,547,000USD37,874,000USD-127,781,000USD-7,500,000USD
    Net Borrowings0USD0USD305,304,000USD0USD0USD-158,000USD—75,000USD
    Total Cash From Financing Activities40,142,000USD17,699,000USD336,600,000USD109,087,000USD73,466,000USD181,288,000USD127,177,000USD59,836,000USD
    Issuance Of Capital Stock0USD0USD216,563,000USD107,367,000USD9,012,000USD131,871,000USD127,177,000USD—
    Change In Cash75,237,000USD-63,398,000USD158,323,000USD-3,337,000USD-10,746,000USD130,116,000USD-39,993,000USD51,963,000USD
    Begin Period Cash Flow222,928,000USD286,326,000USD128,003,000USD131,340,000USD142,086,000USD11,970,000USD51,963,000USD—
    End Period Cash Flow298,165,000USD222,928,000USD286,326,000USD128,003,000USD131,340,000USD142,086,000USD11,970,000USD51,963,000USD
    Other Cashflows From Financing Activities40,142,000USD17,699,000USD-185,388,000USD1,720,000USD66,552,000USD49,417,000USD59,977,000USD49,417,000USD
    Other Cashflows From Investing Activities—-20,000,000USD-20,000,000USD7,978,000USD127,000,000USD38,099,000USD-127,500,000USD-11,250,000USD
    Unclassified Investing Cash Flow—20,993,000USD11,351,000USD-7,978,000USD-17,000,000USD-11,338,000USD127,781,000USD138,750,000USD
    Change To Liabilities———7,639,000USD22,655,000USD3,683,000USD10,058,000USD3,673,500USD
    Dividends Paid———-5,552,000USD0USD——0USD
    Sale Purchase Of Stock———15,585,000USD9,012,000USD131,871,000USD127,177,000USD59,786,000USD
    Cash And Cash Equivalents Changes———-3,349,000USD-10,745,000USD130,087,000USD—0USD
    Unclassified Operating Cash Flow———-6,580,000USD———2,074,000USD
    Unclassified Financing Cash Flow———97,334,000USD-2,098,000USD—-59,977,000USD-49,442,000USD
    Exchange Rate Changes———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductBile Acid Medicines47,522,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductLivmarli128,721,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductBile Acid Medicines46,078,000USD0001759425-26-000037
    Q1 2026Quarterly · 2026-03-31ProductLivmarli113,804,000USD0001759425-26-000037
    Q4 2025Quarterly · 2025-12-31ProductBile Acid Medicines42,545,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLicense And Other Revenue0USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLivmarli106,387,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductBile Acid Medicines161,306,000USD0001759425-26-000013
    FY 2025Yearly · 2025-12-31ProductLicense And Other Revenue0USD0001759425-26-000013
    FY 2025Yearly · 2025-12-31ProductLivmarli360,006,000USD0001759425-26-000013
    Q3 2025Quarterly · 2025-09-30ProductBile Acid Medicines40,775,000USD0001759425-25-000054
    Q3 2025Quarterly · 2025-09-30ProductLicense And Other Revenue0USD0001759425-25-000054
    Q3 2025Quarterly · 2025-09-30ProductLivmarli92,235,000USD0001759425-25-000054
    Q2 2025Quarterly · 2025-06-30ProductBile Acid Medicines39,625,000USD0001759425-25-000041
    Q2 2025Quarterly · 2025-06-30ProductLicense And Other Revenue0USD0001759425-25-000041
    Q2 2025Quarterly · 2025-06-30ProductLivmarli88,160,000USD0001759425-25-000041
    Q1 2025Quarterly · 2025-03-31ProductBile Acid Medicines38,361,000USD0001759425-25-000032
    Q1 2025Quarterly · 2025-03-31ProductLicense And Other Revenue0USD0001759425-25-000032
    Q1 2025Quarterly · 2025-03-31ProductLivmarli73,224,000USD0001759425-25-000032
    Q4 2024Quarterly · 2024-12-31ProductBile Acid Medicines35,337,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductLicense And Other Revenue0USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductLivmarli64,093,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductBile Acid Medicines123,114,000USD0001759425-26-000013
    FY 2024Yearly · 2024-12-31ProductLicense And Other Revenue479,000USD0001759425-26-000013
    FY 2024Yearly · 2024-12-31ProductLivmarli213,295,000USD0001759425-26-000013
    Q3 2024Quarterly · 2024-09-30ProductBile Acid Medicines31,176,000USD0001759425-25-000054
    Q3 2024Quarterly · 2024-09-30ProductLicense And Other Revenue75,000USD0001759425-25-000054
    Q3 2024Quarterly · 2024-09-30ProductLivmarli59,126,000USD0001759425-25-000054
    FY 2023Yearly · 2023-12-31ProductBile Acid Medicines37,079,000USD0001759425-26-000013
    FY 2023Yearly · 2023-12-31ProductLicense And Other Revenue7,500,000USD0001759425-26-000013
    FY 2023Yearly · 2023-12-31ProductLivmarli141,795,000USD0001759425-26-000013
    FY 2022Yearly · 2022-12-31ProductBile Acid Medicines0USD0001759425-25-000014
    FY 2022Yearly · 2022-12-31ProductLicense And Other Revenue2,000,000USD0001759425-25-000014
    FY 2022Yearly · 2022-12-31ProductLivmarli75,062,000USD0001759425-25-000014
    FY 2021Yearly · 2021-12-31ProductLicense16,000,000USD0000950170-23-006715
    FY 2021Yearly · 2021-12-31ProductProduct3,138,000USD0000950170-23-006715

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.